Browsing by Author "Elewa, Hazem"
Now showing items 41-48 of 48
-
The impact of genetic and non-genetic factors on warfarin dose prediction in MENA region: A systematic review
Bader, Loulia Akram; Elewa, Hazem ( Public Library of Science , 2016 , Article Review)Background Warfarin is the most commonly used oral anticoagulant for the treatment and prevention of thromboembolic disorders. Pharmacogenomics studies have shown that variants in CYP2C9 and VKORC1 genes are strongly and ... -
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar
Al-Shaer, Mohammad H.; Mansour, Hanine; Elewa, Hazem; Salameh, Pascale; Iqbal, Fatima ( BioMed Central Ltd. , 2017 , Article)Background Tuberculosis is considered the second most common cause of death due to infectious agent. The currently preferred regimen for treatment of pulmonary tuberculosis (PTB) is isoniazid, rifampin, pyrazinamide, and ... -
Trends in oral anticoagulant use in Qatar: a 5-year experience
Elewa Hazem; Alhaddad, Amani; Al-Rawi, Safa; Nounou, Amir; Mahmoud, Hesham; Singh, Rajvir... more authors ... less authors ( Springer New York LLC , 2017 , Article)In Qatar, dabigatran was introduced in 2011 followed by rivaroxaban in 2014. In this study, we aim to explore the trends in oral anticoagulant use in Qatar over the past 5 years and to what extent did DOACs replace warfarin. ... -
Trends of use of SGLT2 inhibitors in Qatar
Zaghloul, Nancy; Awaisu, Ahmed; Mahfouz, Ahmed; Al Saadi, Sumaya; Elewa, Hazem ( Qatar University Press , 2021 , Poster)Background: Type 2 diabetes mellitus (T2DM) represents a growing health challenge in Qatar and worldwide. T2DM is associated with a high risk of cardiovascular (CV) morbidity and mortality, and progression of renal disease. ... -
Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination
Elewa, Hazem; Ahmed, Dina; Barnes, Geoffrey D. ( Thieme Medical Publishers, Inc. , 2016 , Article)Patients with atrial fibrillation (AF) who are treated with oral anticoagulants often have concurrent coronary artery disease. Triple oral antithrombotic therapy (TOAT) is often necessity to prevent stent thrombosis or ... -
Vancomycin therapeutic drug monitoring service quality indices and clinical effectiveness outcomes: A retrospective cohort and clinical audit
Al-Sulaiti, Fatima K.; Nader, Ahmed; El-Mekaty, Eman; Elewa, Hazem; Al-Badriyeh, Daoud; El-Zubair, Ahmed; Saad, Mohamed O.; Awaisu, Ahmed... more authors ... less authors ( Blackwell Publishing Ltd , 2020 , Article)Introduction: Vancomycin is commonly used for the treatment of complicated infections caused by methicillin-resistant Staphylococcus aureus. The impact of vancomycin therapeutic drug monitoring (TDM) quality indices on ... -
Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review
Fahmi, Amr Mohamed; Elewa, Hazem; El Jilany, Islam ( Springer , 2022 , Article Review)Background For decades, vitamin K antagonists and specifically warfarin, have been the sole agents used orally to manage thromboembolic conditions, including stroke and venous thromboembolism (VTE). Several factors lead ... -
Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case–Control Study
Salem, Muhammad; El-Bardissy, Ahmed; Elshafei, Mohamed Nabil; Khalil, Ahmed; Mahmoud, Hesham; Fahmi, Amr Mohamed; Kasem, Mohamed; Bader, Loulia; Sherbash, Mohamed; Elawady, Mostafa Ibrahim; Abdalazim, Walaa; Howady, Faraj; Elewa, Hazem... more authors ... less authors ( Wiley-Blackwell , 2023 , Article)Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase ...